Cargando…

Zanubrutinib: past, present, and future

In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be approved, and it changed the standard-of-care treatment for diseases such as chronic lymphocytic leukemia, ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Constantine S., Muñoz, Javier L., Seymour, John F., Opat, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495438/
https://www.ncbi.nlm.nih.gov/pubmed/37696810
http://dx.doi.org/10.1038/s41408-023-00902-x